
Multiple Sclerosis
Latest News

Latest Videos

Shorts










CME Content
More News

A neuroimmunology fellow at the Cleveland Clinic shared her experience attending the 2026 ACTRIMS Forum, specifically focusing on the late-breaking data presented in multiple sclerosis.

The director of the Neurology Residency Program at the Marcus Neuroscience Institute discussed the importance of early recognition of invisible symptoms in comprehensive multiple sclerosis care. [WATCH TIME: 9 minutes]

A neuroimmunology fellow at the Cleveland Clinic reflected on the 2026 ACTRIMS Forum, highlighting key takeaways in multiple sclerosis research presented in the program. [WATCH TIME: 6 minutes]

Constance V. Katsafanas, DO, director of the Neurology Residency Program at the Marcus Neuroscience Institute, highlighted the importance of individualized treatment strategies in multiple sclerosis.

The director of the Neurology Residency Program at the Marcus Neuroscience Institute detailed the importance of tailoring treatment to patients with multiple sclerosis. [WATCH TIME: 5 minutes]

Apply for a $40,000 international MS research award honoring senior women scientists advancing care for women; submissions close June 12, 2026.

The assistant professor of medicine at the University of Toronto discussed population-level evidence suggesting MS may precede EBV infection in rare cases and its implications for disease pathogenesis and diagnosis.

The professor of neurology at Cleveland Clinic’s Mellen Center for MS provided thoughts on how radiologic biomarkers may help shape the next generation of multiple sclerosis clinical trials. [WATCH TIME: 3 minutes]

A clinician and researcher at the University of California, San Francisco highlighted how agentic AI frameworks are being integrated into real-world multiple sclerosis research to streamline big data analysis and accelerate clinically meaningful discovery. [Watch Time: 5 minutes]

Full data from the FENhance studies of fenebrutinib will be presented at the 2026 American Academy of Neurology Annual Meeting and submitted for regulatory review along with FENtrepid data in multiple sclerosis.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending February 27, 2026.

The senior research investigator at the New York Stem Cell Foundation answered questions about the research efforts needed to advance iPSC human models toward clinical relevance for patients with multiple sclerosis. [WATCH TIME: 4 minutes]

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending February 20, 2026.

The professor of neurology at Cleveland Clinic gave insights on hematopoietic stem cell transplantation, CAR T-cell strategies, and the ongoing challenges of developing immune reconstitution and repair therapies in multiple sclerosis.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending February 13, 2026.

Phase 2 MoonStone trial shows obexelimab sharply cuts new MRI lesions in relapsing MS by week 12, with convenient, weekly self-injection.

In the phase 3 PERSEUS trial, BTK inhibitor tolebrutinib did not significantly reduce disability progression compared with placebo in patients with primary progressive multiple sclerosis.

New results presented at ACTRIMS showed that in the phase 3 FENtrepid study, fenebrutinib was noninferior to ocrelizumab in reducing disability progression in primary progressive multiple sclerosis.

A nurse practitioner at the Rocky Mountain MS Clinic discussed emerging therapeutics, evolving management strategies, and unmet needs in multiple sclerosis, specifically in women’s health.




















